When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is that not only is this terrible for patient health, it can be more costly in the end.
Is a private-label product really better once you factor in performance, durability, and everything it takes to support it? Sometimes yes and sometimes no. The job is knowing the difference.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
The increasing costs of labor and supplies are the top issues keeping healthcare CFOs up at night, according to a new report. Even though providers' margins are currently quite tight, the report recommended that healthcare organizations adopt data analytics software to remedy these concerns and help with important decisions like how to effectively manage their existing workforce and where to shift care delivery models.
There is no single driver of low-value care — providers, systems, and patients all play a role. But with the right tools, stakeholders can work together to re-align incentives and transform our healthcare delivery system into one that prioritizes value, eliminates waste and leads to better overall patient outcomes.
The report found that Aimmune's AR101 and DBV's Viaskin Peanut lacked sufficient evidence to demonstrate that their benefits outweighed short-term risks. Aimmune and an allergy advocacy group criticized the report.